Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant | Aplastic Anemia and MDS International Foundation

Clinical Trial: NCT02396134

Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

This randomized phase II trial studies how well vaccine therapy works in reducing the frequency of cytomegalovirus severe infections (events) in patients with hematologic malignancies undergoing donor stem cell transplant. Vaccines made from a peptide may help the body build an effective immune response and may reduce cytomegalovirus events after donor stem cell transplant.

Status: 
Recruiting
Study Date: 
Fri, 05/01/2015 to Wed, 05/01/2019
Bone Marrow Disease(s): 
myelodysplastic syndromes (MDS)
Intervention: 
Biological: CMVpp65-A*0201 peptide vaccine Given SC Other: Placebo Given SC Other Name: PLCB Other: Laboratory Biomarker Analysis Correlative studies